Ethnic variation in toxicity and outcome of adjuvant chemoradiation for gastric cancer in Israel

Ronen M. Brenner*, Shaye Kivity, Yulia Kundel, Ofer Purim, Nir Peled, Efraim Idelevich, Konstantin Lavrenkov, Svetlana Kovel, Eyal Fenig, Aaron Sulkes, Baruch Brenner

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Background: Data on differences in toxicity and efficacy of chemotherapy and radiotherapy among different ethnic groups is limited. We evaluated differences in toxicity, tolerability and clinical outcome of Ashkenazi and non-Ashkenazi Jews receiving postoperative chemoradiation for locally advanced gastric cancer (LAGC). Patients and Methods: Between 6/2000-12/2007, 84 Ashkenazi patients and 60 non-Ashkenazi patients underwent chemoradiation following resection of LAGC (INT-116 trial). Results: Patients' and tumor characteristics were comparable. Ashkenazi patients experienced significantly higher rates of fatigue, anorexia, and grade 3-4 dysphagia, as well as a trend for a higher rate of diarrhea. The incidence of other toxicities, dose adjustments of chemotherapy and radiotherapy and patient prognosis did not differ. Conclusion: This study shows higher rates of various toxicities among Ashkenazi patients receiving postoperative chemoradiation for LAGC compared to non-Ashkenazi patients. To our knowledge, this is the first study comparing treatment toxicity, tolerability and outcome between these two groups.

Original languageEnglish
Pages (from-to)5151-5157
Number of pages7
JournalAnticancer Research
Issue number11
StatePublished - Nov 2013


  • Ashkenazi
  • Chemoradiation
  • Ethnicity
  • Gastric cancer
  • Israel


Dive into the research topics of 'Ethnic variation in toxicity and outcome of adjuvant chemoradiation for gastric cancer in Israel'. Together they form a unique fingerprint.

Cite this